Hematogenous metastasis: Roles of CD44v and alternative sialofucosylated selectin ligands

K Konstantopoulos, Susan N. Thomas

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

P-selectin, expressed on activated endothelial cells and platelets, is a transmembrane glycoprotein (GP) that mediates, among others, host cell-tumor cell adhesion relevant to the process of hematogenous metastasis. The most compelling evidence for a direct role of P-selectin in the metastatic process is the pronounced inhibition of metastasis in P-selectin-deficient mice compared to wild-type controls in a colon carcinoma cell model [1-3]. Along these lines, enzymatic removal of P-selectin ligands from the colon carcinoma cell surface results in a pronounced reduction of experimental metastasis [1]. Although molecules that bind P-selectin have previously been identified in tumor cell lines [4-6], their functional roles and biological significance have not been substantiated. As has been appropriately argued in the literature [7], distinctions must be made between molecules that can bind to P-selectin under static conditions in vitro, and functional ligands that do interact with P-selectin under fluid dynamic conditions in vivo. By identifying the functional P-selectin ligand(s) on colon carcinoma cells, using an integrated approach consisting of bioengineering tools and contemporary biochemistry and molecular biology techniques, we provide guidelines for engineering novel therapeutic agents that selectively block tumor cell ligand binding function and thus interfere with metastatic spread. Such a strategy may offer specific antimetastatic efficacy without impairing other important P-selectin-mediated physiological processes [8, 9]. Alternatively, these molecules could be utilized in a targeted drug-delivery approach, which would aim at selectively or preferentially eradicating colon carcinoma cells from the vasculature.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
Pages601-619
Number of pages19
Volume705
DOIs
StatePublished - 2011

Publication series

NameAdvances in Experimental Medicine and Biology
Volume705
ISSN (Print)00652598

Fingerprint

Selectins
P-Selectin
Neoplasm Metastasis
Ligands
Cells
Colon
Carcinoma
Tumors
Molecules
Physiological Phenomena
Bioengineering
Biochemistry
Molecular biology
Cell adhesion
Endothelial cells
Hydrodynamics
Platelets
Fluid dynamics
Tumor Cell Line
Cell Adhesion

Keywords

  • CD44
  • Colon carcinoma cells
  • Metastasis
  • Selectin
  • Shear flow

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Konstantopoulos, K., & Thomas, S. N. (2011). Hematogenous metastasis: Roles of CD44v and alternative sialofucosylated selectin ligands. In Advances in Experimental Medicine and Biology (Vol. 705, pp. 601-619). (Advances in Experimental Medicine and Biology; Vol. 705). https://doi.org/10.1007/978-1-4419-7877-6_32

Hematogenous metastasis : Roles of CD44v and alternative sialofucosylated selectin ligands. / Konstantopoulos, K; Thomas, Susan N.

Advances in Experimental Medicine and Biology. Vol. 705 2011. p. 601-619 (Advances in Experimental Medicine and Biology; Vol. 705).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Konstantopoulos, K & Thomas, SN 2011, Hematogenous metastasis: Roles of CD44v and alternative sialofucosylated selectin ligands. in Advances in Experimental Medicine and Biology. vol. 705, Advances in Experimental Medicine and Biology, vol. 705, pp. 601-619. https://doi.org/10.1007/978-1-4419-7877-6_32
Konstantopoulos K, Thomas SN. Hematogenous metastasis: Roles of CD44v and alternative sialofucosylated selectin ligands. In Advances in Experimental Medicine and Biology. Vol. 705. 2011. p. 601-619. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-7877-6_32
Konstantopoulos, K ; Thomas, Susan N. / Hematogenous metastasis : Roles of CD44v and alternative sialofucosylated selectin ligands. Advances in Experimental Medicine and Biology. Vol. 705 2011. pp. 601-619 (Advances in Experimental Medicine and Biology).
@inproceedings{5a6505b6a0b54644b483028b32904559,
title = "Hematogenous metastasis: Roles of CD44v and alternative sialofucosylated selectin ligands",
abstract = "P-selectin, expressed on activated endothelial cells and platelets, is a transmembrane glycoprotein (GP) that mediates, among others, host cell-tumor cell adhesion relevant to the process of hematogenous metastasis. The most compelling evidence for a direct role of P-selectin in the metastatic process is the pronounced inhibition of metastasis in P-selectin-deficient mice compared to wild-type controls in a colon carcinoma cell model [1-3]. Along these lines, enzymatic removal of P-selectin ligands from the colon carcinoma cell surface results in a pronounced reduction of experimental metastasis [1]. Although molecules that bind P-selectin have previously been identified in tumor cell lines [4-6], their functional roles and biological significance have not been substantiated. As has been appropriately argued in the literature [7], distinctions must be made between molecules that can bind to P-selectin under static conditions in vitro, and functional ligands that do interact with P-selectin under fluid dynamic conditions in vivo. By identifying the functional P-selectin ligand(s) on colon carcinoma cells, using an integrated approach consisting of bioengineering tools and contemporary biochemistry and molecular biology techniques, we provide guidelines for engineering novel therapeutic agents that selectively block tumor cell ligand binding function and thus interfere with metastatic spread. Such a strategy may offer specific antimetastatic efficacy without impairing other important P-selectin-mediated physiological processes [8, 9]. Alternatively, these molecules could be utilized in a targeted drug-delivery approach, which would aim at selectively or preferentially eradicating colon carcinoma cells from the vasculature.",
keywords = "CD44, Colon carcinoma cells, Metastasis, Selectin, Shear flow",
author = "K Konstantopoulos and Thomas, {Susan N.}",
year = "2011",
doi = "10.1007/978-1-4419-7877-6_32",
language = "English (US)",
isbn = "9781441978769",
volume = "705",
series = "Advances in Experimental Medicine and Biology",
pages = "601--619",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - GEN

T1 - Hematogenous metastasis

T2 - Roles of CD44v and alternative sialofucosylated selectin ligands

AU - Konstantopoulos, K

AU - Thomas, Susan N.

PY - 2011

Y1 - 2011

N2 - P-selectin, expressed on activated endothelial cells and platelets, is a transmembrane glycoprotein (GP) that mediates, among others, host cell-tumor cell adhesion relevant to the process of hematogenous metastasis. The most compelling evidence for a direct role of P-selectin in the metastatic process is the pronounced inhibition of metastasis in P-selectin-deficient mice compared to wild-type controls in a colon carcinoma cell model [1-3]. Along these lines, enzymatic removal of P-selectin ligands from the colon carcinoma cell surface results in a pronounced reduction of experimental metastasis [1]. Although molecules that bind P-selectin have previously been identified in tumor cell lines [4-6], their functional roles and biological significance have not been substantiated. As has been appropriately argued in the literature [7], distinctions must be made between molecules that can bind to P-selectin under static conditions in vitro, and functional ligands that do interact with P-selectin under fluid dynamic conditions in vivo. By identifying the functional P-selectin ligand(s) on colon carcinoma cells, using an integrated approach consisting of bioengineering tools and contemporary biochemistry and molecular biology techniques, we provide guidelines for engineering novel therapeutic agents that selectively block tumor cell ligand binding function and thus interfere with metastatic spread. Such a strategy may offer specific antimetastatic efficacy without impairing other important P-selectin-mediated physiological processes [8, 9]. Alternatively, these molecules could be utilized in a targeted drug-delivery approach, which would aim at selectively or preferentially eradicating colon carcinoma cells from the vasculature.

AB - P-selectin, expressed on activated endothelial cells and platelets, is a transmembrane glycoprotein (GP) that mediates, among others, host cell-tumor cell adhesion relevant to the process of hematogenous metastasis. The most compelling evidence for a direct role of P-selectin in the metastatic process is the pronounced inhibition of metastasis in P-selectin-deficient mice compared to wild-type controls in a colon carcinoma cell model [1-3]. Along these lines, enzymatic removal of P-selectin ligands from the colon carcinoma cell surface results in a pronounced reduction of experimental metastasis [1]. Although molecules that bind P-selectin have previously been identified in tumor cell lines [4-6], their functional roles and biological significance have not been substantiated. As has been appropriately argued in the literature [7], distinctions must be made between molecules that can bind to P-selectin under static conditions in vitro, and functional ligands that do interact with P-selectin under fluid dynamic conditions in vivo. By identifying the functional P-selectin ligand(s) on colon carcinoma cells, using an integrated approach consisting of bioengineering tools and contemporary biochemistry and molecular biology techniques, we provide guidelines for engineering novel therapeutic agents that selectively block tumor cell ligand binding function and thus interfere with metastatic spread. Such a strategy may offer specific antimetastatic efficacy without impairing other important P-selectin-mediated physiological processes [8, 9]. Alternatively, these molecules could be utilized in a targeted drug-delivery approach, which would aim at selectively or preferentially eradicating colon carcinoma cells from the vasculature.

KW - CD44

KW - Colon carcinoma cells

KW - Metastasis

KW - Selectin

KW - Shear flow

UR - http://www.scopus.com/inward/record.url?scp=80054023220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054023220&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-7877-6_32

DO - 10.1007/978-1-4419-7877-6_32

M3 - Conference contribution

C2 - 21618132

AN - SCOPUS:80054023220

SN - 9781441978769

VL - 705

T3 - Advances in Experimental Medicine and Biology

SP - 601

EP - 619

BT - Advances in Experimental Medicine and Biology

ER -